Atezolizumab for carcinoma, neuroendocrine

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 18 Jan 2022: Trial started, NCT05470595
  2. 22 Jul 2022: Trial registered, NCT05470595

The trials

NCT05470595: A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung

State
Under way
Phase
Phase 2
People
67 planned
Started
18 Jan 2022
Primary completion
31 Jan 2028
Arms
Atezolizumab/Platinum/Etoposide
Results
None posted
  1. 18 Jan 2022: Trial started
  2. 22 Jul 2022: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.